Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"$278.0 million","upfrontCash":"$266.0 million","newsHeadline":"Takeda to Divest Select APAC Assets to Celltrion for $278M","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Teijin Pharma","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Alogliptin

    Menu

    Alogliptin

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Takeda Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited

              Details:

              The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

              Lead Product(s): Alogliptin Benzoate,Pioglitazone

              Therapeutic Area: Endocrinology Product Name: Liovel

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Teijin Pharma

              Deal Size: $1,250.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment April 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Takeda Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

              Details:

              The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

              Lead Product(s): Alogliptin Benzoate

              Therapeutic Area: Endocrinology Product Name: Nesina

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Teijin Pharma

              Deal Size: $1,250.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment February 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Takeda Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda to Divest Select APAC Assets to Celltrion for $278M

              Details:

              The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.

              Lead Product(s): Alogliptin Benzoate

              Therapeutic Area: Endocrinology Product Name: Nesina

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Celltrion

              Deal Size: $278.0 million Upfront Cash: $266.0 million

              Deal Type: Divestment June 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Metrochem Alogliptin Benzoate
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY